Ling-Mei Wang,
President and COO
Ling-Mei Wang is the President and COO of Steminent Biotherapeutics in Taiwan, the leading Phase-2 stage company dedicated to the development of novel cellular therapeutics for the treatment of diseases with unmet or under-served medical needs. Steminent utilizes its proprietary Stemchymal® platform to manufacture standardized stem cell products of the highest quality for research and clinical development in neurodegenerative, liver, and other therapeutic areas. To further advance its technologies, the company is taking a distributed R&D model by closely collaborating with researchers of UHN, Canada and other medical institutes.
Ling-Mei has over 25 years of R&D and management experiences in a wide spectrum of research area including cancer, human genomics and regenerative medicine in both academic and industrial sectors. Prior to joining SBI, Ling-Mei held a list of managerial positions including the Vice-President of CHO Pharma Inc., the COO and the CTO of Taiwan Supra Integration and Incubation Center (Si2C), the Deputy General Director and the CTO at Biomedical Technology and Device Research Laboratories of Industrial Technology Research Institute (ITRI), the Associate Principal Investigator at National Health Research Institute (NHRI), and the Director of R&D at Vita Genomics. Ling-Mei received her Ph.D. degree from University of Texas Health Science Center at San Antonio, USA, and was a researcher at National Cancer Institute in USA for 10 years before returning to Taiwan.
|
|
|
